4.8 Article

Immune effector monocyte-neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1907660116

Keywords

metastatic breast cancer; immune effector monocytes; CCR2; CCL2; STING

Funding

  1. National Cancer Institute [CA057621, CA180039, CA199315, CA190851]
  2. Parker Institute for Immunotherapy
  3. Tegger Foundation
  4. Wenner-Gren Foundations
  5. Sweden-America Foundation
  6. Swedish Society of Medicine
  7. Lakaresallskapet i Lund
  8. Swedish Society for Medical Research
  9. Becas Chile Scholarship
  10. Taiwan Ministry of Science and Technology [MOST104-2917-I-006-002]

Ask authors/readers for more resources

Metastatic behavior varies significantly among breast cancers. Mechanisms explaining why the majority of breast cancer patients never develop metastatic outgrowth are largely lacking but could underlie the development of novel immunotherapeutic target molecules. Here we show interplay between nonmetastatic primary breast cancer and innate immune response, acting together to control metastatic progression. The primary tumor systemically recruits IFN gamma-producing immune effector monocytes to the lung. IFN gamma up-regulates Tmem173/STING in neutrophils and enhances their killing capacity. The immune effector monocytes and tumoricidal neutrophils target disseminated tumor cells in the lungs, preventing metastatic outgrowth. Importantly, our findings could underlie the development of immunotherapeutic target molecules that augment the function of immune effector monocytes and neutrophils.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available